Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells.
Interferon β-1b directly modulates human neural stem/progenitor cell fate.
Prevalence of neurological disorders in Al Quseir, Egypt: methodological aspects.
GEMS Project: A Platform to Investigate Multiple Sclerosis Risk.
Glatiramer acetate, an anti-demyelination drug, reduced rats' epileptic seizures induced by pentylenetetrazol via protection of myelin sheath.
Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate.
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma.
Gait Mechanics are Different between Healthy Controls and Patients with Multiple Sclerosis.
Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis.
Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation.
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate.
Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Genzyme’s LEMTRADA™ (alemtuzumab) application for MS accepted for review by the FDA
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
New insights into signaling during myelination in zebrafish.
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation.
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.

Pages